Collegium Pharmaceutical (COLL) Competitors

$34.22 +0.60 (+1.78%)

Closing price 05/20/2026 04:00 PM Eastern

Extended Trading

$33.98 -0.23 (-0.69%)

As of 07:22 AM Eastern

COLL vs. INDV, DNTH, KNSA, NAMS, and AMRX

Should you buy Collegium Pharmaceutical stock or one of its competitors? MarketBeat compares Collegium Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Collegium Pharmaceutical include Indivior (INDV), Dianthus Therapeutics (DNTH), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry.

How does Collegium Pharmaceutical compare to Indivior?

Collegium Pharmaceutical (NASDAQ:COLL) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Collegium Pharmaceutical presently has a consensus target price of $57.50, suggesting a potential upside of 68.03%. Indivior has a consensus target price of $39.33, suggesting a potential upside of 4.64%. Given Collegium Pharmaceutical's higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

60.3% of Indivior shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Indivior has a net margin of 19.44% compared to Collegium Pharmaceutical's net margin of 9.41%. Collegium Pharmaceutical's return on equity of 95.18% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Indivior	19.44%	-219.26%	29.40%

In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Indivior. MarketBeat recorded 5 mentions for Collegium Pharmaceutical and 3 mentions for Indivior. Collegium Pharmaceutical's average media sentiment score of 0.29 beat Indivior's score of 0.25 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Indivior has higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.42	$62.87M	$2.04	16.77
Indivior	$1.24B	3.70	$210M	$1.95	19.28

Collegium Pharmaceutical has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Indivior has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Summary

Indivior beats Collegium Pharmaceutical on 11 of the 17 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Dianthus Therapeutics?

Collegium Pharmaceutical (NASDAQ:COLL) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 5 mentions for Collegium Pharmaceutical and 3 mentions for Dianthus Therapeutics. Collegium Pharmaceutical's average media sentiment score of 0.29 beat Dianthus Therapeutics' score of 0.20 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dianthus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.5% of Dianthus Therapeutics shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Collegium Pharmaceutical has a net margin of 9.41% compared to Dianthus Therapeutics' net margin of -12,998.50%. Collegium Pharmaceutical's return on equity of 95.18% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

Collegium Pharmaceutical has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.42	$62.87M	$2.04	16.77
Dianthus Therapeutics	$2.04M	2,377.61	-$162.34M	-$4.13	N/A

Collegium Pharmaceutical currently has a consensus price target of $57.50, suggesting a potential upside of 68.03%. Dianthus Therapeutics has a consensus price target of $117.82, suggesting a potential upside of 32.80%. Given Collegium Pharmaceutical's higher probable upside, equities analysts plainly believe Collegium Pharmaceutical is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Collegium Pharmaceutical has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

Summary

Collegium Pharmaceutical beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Kiniksa Pharmaceuticals International?

Collegium Pharmaceutical (NASDAQ:COLL) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 5 mentions for Collegium Pharmaceutical and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.19 beat Collegium Pharmaceutical's score of 0.29 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Collegium Pharmaceutical has higher revenue and earnings than Kiniksa Pharmaceuticals International. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.42	$62.87M	$2.04	16.77
Kiniksa Pharmaceuticals International	$677.56M	6.16	$59.01M	$0.90	60.31

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Collegium Pharmaceutical's net margin of 9.41%. Collegium Pharmaceutical's return on equity of 95.18% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Collegium Pharmaceutical has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

Collegium Pharmaceutical currently has a consensus target price of $57.50, suggesting a potential upside of 68.03%. Kiniksa Pharmaceuticals International has a consensus target price of $60.86, suggesting a potential upside of 12.12%. Given Collegium Pharmaceutical's higher probable upside, research analysts clearly believe Collegium Pharmaceutical is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Collegium Pharmaceutical and Kiniksa Pharmaceuticals International tied by winning 8 of the 16 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Collegium Pharmaceutical has a net margin of 9.41% compared to NewAmsterdam Pharma's net margin of -943.23%. Collegium Pharmaceutical's return on equity of 95.18% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

NewAmsterdam Pharma has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	185.74	-$203.82M	-$1.79	N/A
Collegium Pharmaceutical	$780.57M	1.42	$62.87M	$2.04	16.77

NewAmsterdam Pharma presently has a consensus target price of $48.00, indicating a potential upside of 34.27%. Collegium Pharmaceutical has a consensus target price of $57.50, indicating a potential upside of 68.03%. Given Collegium Pharmaceutical's higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 5 mentions for Collegium Pharmaceutical and 1 mentions for NewAmsterdam Pharma. Collegium Pharmaceutical's average media sentiment score of 0.29 beat NewAmsterdam Pharma's score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Collegium Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.9% of NewAmsterdam Pharma shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Collegium Pharmaceutical beats NewAmsterdam Pharma on 11 of the 17 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

Collegium Pharmaceutical has a net margin of 9.41% compared to Amneal Pharmaceuticals' net margin of 4.01%. Collegium Pharmaceutical's return on equity of 95.18% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Amneal Pharmaceuticals presently has a consensus price target of $15.17, suggesting a potential upside of 24.01%. Collegium Pharmaceutical has a consensus price target of $57.50, suggesting a potential upside of 68.03%. Given Collegium Pharmaceutical's higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Amneal Pharmaceuticals has higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.29	$72.06M	$0.38	32.18
Collegium Pharmaceutical	$780.57M	1.42	$62.87M	$2.04	16.77

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

In the previous week, Amneal Pharmaceuticals had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 5 mentions for Collegium Pharmaceutical. Amneal Pharmaceuticals' average media sentiment score of 1.04 beat Collegium Pharmaceutical's score of 0.29 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Amneal Pharmaceuticals beats Collegium Pharmaceutical on 10 of the 16 factors compared between the two stocks.

Get Collegium Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COLL vs. The Competition

Export

Metric	Collegium Pharmaceutical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.09B	$2.99B	$6.30B	$12.11B
Dividend Yield	N/A	1.97%	2.80%	5.36%
P/E Ratio	16.77	17.63	20.82	25.31
Price / Sales	1.42	248.41	518.38	71.03
Price / Cash	2.21	56.99	43.18	55.00
Price / Book	3.55	4.53	9.87	6.94
Net Income	$62.87M	$74.99M	$3.55B	$335.25M
7 Day Performance	-1.75%	-3.81%	-0.83%	-1.39%
1 Month Performance	2.86%	-5.39%	-1.18%	0.09%
1 Year Performance	16.12%	35.50%	33.67%	32.51%

Collegium Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COLL Collegium Pharmaceutical	2.8246 of 5 stars	$34.22 +1.8%	$57.50 +68.0%	+14.2%	$1.09B	$780.57M	16.77	210
INDV Indivior	3.4914 of 5 stars	$38.84 -1.7%	$39.33 +1.3%	+228.6%	$4.82B	$1.24B	19.92	1,051
DNTH Dianthus Therapeutics	2.5353 of 5 stars	$87.12 +0.5%	$117.82 +35.2%	+364.3%	$4.74B	$2.04M	N/A	80
KNSA Kiniksa Pharmaceuticals International	4.0201 of 5 stars	$58.37 -0.4%	$60.86 +4.3%	+103.3%	$4.51B	$677.56M	64.86	220	Positive News Analyst Upgrade
NAMS NewAmsterdam Pharma	2.0915 of 5 stars	$39.59 +2.2%	$48.00 +21.2%	+84.8%	$4.45B	$22.50M	N/A	4	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COLL) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Collegium Pharmaceutical (COLL) Competitors

COLL vs. INDV, DNTH, KNSA, NAMS, and AMRX

How does Collegium Pharmaceutical compare to Indivior?

Summary

How does Collegium Pharmaceutical compare to Dianthus Therapeutics?

Summary

How does Collegium Pharmaceutical compare to Kiniksa Pharmaceuticals International?

Summary

How does Collegium Pharmaceutical compare to NewAmsterdam Pharma?

Summary

How does Collegium Pharmaceutical compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Collegium Pharmaceutical (COLL) Competitors

COLL vs. INDV, DNTH, KNSA, NAMS, and AMRX

How does Collegium Pharmaceutical compare to Indivior?

Do analysts recommend COLL or INDV?

Do institutionals and insiders have more ownership in COLL or INDV?

Is COLL or INDV more profitable?

Does the media refer more to COLL or INDV?

Which has stronger earnings & valuation, COLL or INDV?

Which has more volatility and risk, COLL or INDV?

Summary

How does Collegium Pharmaceutical compare to Dianthus Therapeutics?

Does the media favor COLL or DNTH?

Do institutionals and insiders believe in COLL or DNTH?

Is COLL or DNTH more profitable?

Which has higher earnings and valuation, COLL or DNTH?

Do analysts rate COLL or DNTH?

Which has more risk & volatility, COLL or DNTH?

Summary

How does Collegium Pharmaceutical compare to Kiniksa Pharmaceuticals International?

Does the media refer more to COLL or KNSA?

Which has better earnings & valuation, COLL or KNSA?

Is COLL or KNSA more profitable?

Do institutionals & insiders hold more shares of COLL or KNSA?

Which has more risk & volatility, COLL or KNSA?

Do analysts prefer COLL or KNSA?

Summary

How does Collegium Pharmaceutical compare to NewAmsterdam Pharma?

Is NAMS or COLL more profitable?

Which has more risk & volatility, NAMS or COLL?

Which has stronger earnings and valuation, NAMS or COLL?

Do analysts rate NAMS or COLL?

Does the media favor NAMS or COLL?

Do institutionals and insiders have more ownership in NAMS or COLL?

Summary

How does Collegium Pharmaceutical compare to Amneal Pharmaceuticals?

Is AMRX or COLL more profitable?

Do analysts rate AMRX or COLL?

Which has better earnings and valuation, AMRX or COLL?

Do institutionals & insiders hold more shares of AMRX or COLL?

Which has more risk and volatility, AMRX or COLL?

Does the media favor AMRX or COLL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools